ŠIMEK, Matěj, Kristina NEŠPOROVÁ, Anna KOCURKOVÁ, Tereza FOGLOVÁ, Gabriela AMBROŽOVÁ, Vladimír VELEBNÝ, Lukáš KUBALA a Martina HERMANNOVÁ. How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy. Carbohydrate Polymers. Oxford: Elsevier Ltd., 2021, roč. 263, July, s. "117927", 10 s. ISSN 0144-8617. Dostupné z: https://dx.doi.org/10.1016/j.carbpol.2021.117927. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1769457, author = {Šimek, Matěj and Nešporová, Kristina and Kocurková, Anna and Foglová, Tereza and Ambrožová, Gabriela and Velebný, Vladimír and Kubala, Lukáš and Hermannová, Martina}, article_location = {Oxford}, article_number = {July}, doi = {http://dx.doi.org/10.1016/j.carbpol.2021.117927}, keywords = {Hyaluronan; Pharmacokinetics; Molecular weight; Stable isotope; Metabolism}, language = {eng}, issn = {0144-8617}, journal = {Carbohydrate Polymers}, title = {How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy}, url = {https://doi.org/10.1016/j.carbpol.2021.117927}, volume = {263}, year = {2021} }
TY - JOUR ID - 1769457 AU - Šimek, Matěj - Nešporová, Kristina - Kocurková, Anna - Foglová, Tereza - Ambrožová, Gabriela - Velebný, Vladimír - Kubala, Lukáš - Hermannová, Martina PY - 2021 TI - How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy JF - Carbohydrate Polymers VL - 263 IS - July SP - "117927" EP - "117927" PB - Elsevier Ltd. SN - 01448617 KW - Hyaluronan KW - Pharmacokinetics KW - Molecular weight KW - Stable isotope KW - Metabolism UR - https://doi.org/10.1016/j.carbpol.2021.117927 N2 - There is inconsistent information regarding the size effects of exogenously given hyaluronan on its in vivo fate. The data are often biased by the poor quality of hyaluronan and non-ideal labelling strategies used for resolving exogenous/endogenous hyaluronan, which only monitor the label and not hyaluronan itself. To overcome these drawbacks and establish the pharmacokinetics of intravenous hyaluronan in relation to its Mw, 13C-labelled HA of five Mws from 13.6–1562 kDa was prepared and administered to mice at doses 25−50 mg kg–1. The elimination efficiency increased with decreasing Mw. Low Mw hyaluronan was rapidly eliminated as small hyaluronan fragments in urine, while high Mw hyaluronan exhibited saturable kinetics and complete metabolization within 48 h. All tested Mws exhibited a similar uptake by liver cells and metabolization into activated sugars. 13C-labelling combined with LC–MS provides an excellent approach to elucidating in vivo fate and biological activities of hyaluronan. ER -
ŠIMEK, Matěj, Kristina NEŠPOROVÁ, Anna KOCURKOVÁ, Tereza FOGLOVÁ, Gabriela AMBROŽOVÁ, Vladimír VELEBNÝ, Lukáš KUBALA a Martina HERMANNOVÁ. How the molecular weight affects the in vivo fate of exogenous hyaluronan delivered intravenously: A stable-isotope labelling strategy. \textit{Carbohydrate Polymers}. Oxford: Elsevier Ltd., 2021, roč.~263, July, s.~''117927'', 10 s. ISSN~0144-8617. Dostupné z: https://dx.doi.org/10.1016/j.carbpol.2021.117927.
|